RetroSense Therapeutics Receives $6,000,000 Series A Funding Round
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=43be5801-b784-4fdc-918a-9fb5b49c9259
Date 1/10/2015
Company Name RetroSense Therapeutics
Mailing Address 330 East Liberty Street LL Ann Arbor, MI 48104 USA
Company Description Led by a team of seasoned veterans, RetroSense Therapeutics was founded in 2009 to develop a novel gene therapy approach to vision restoration.
Proceeds Purposes The company intends to use the funds to enable completion of preclinical studies needed to support an Investigational New Drug (IND) filing with the U.S. Food and Drug Administration for its lead compound, RST-001 for the treatment of Retinitis Pigmentosa, a cause of vision loss and blindness.